Treatment for high-risk smoldering myeloma

New England Journal of Medicine

Volumn 369, Issue 18, 2013, Pages 1762-1765

  Kristinsson, Sigurdur Y ^a   Holmberg, Erik ^b   Blimark, Cecilie ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; M PROTEIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE;

CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; DRUG RESPONSE; HUMAN; LETTER; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SMOLDERING MULTIPLE MYELOMA; TREATMENT OUTCOME; CANCER GROWTH; HIGH RISK PATIENT; PLASMA CELL; PROTEIN BLOOD LEVEL; RISK FACTOR; STEM CELL MOBILIZATION; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; FEMALE; MALE; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 84886743326     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1310911     Document Type: Letter

References (5)

1. Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013;369:438-47.
2. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011;117:5573-81.
3. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785-9.
4. Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110:2586-92.
5. Cherry BM, Korde N, Kwok M, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 2013;54:2215-8.